Drug Profile
Research programme: tyrosine kinase receptor inhibitors - Eli Lilly and Company
Alternative Names: LY 2401401Latest Information Update: 24 Mar 2009
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Small molecules
- Mechanism of Action Angiogenesis inhibitors; Receptor protein-tyrosine kinase antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 07 May 2007 Preclinical trials in Cancer in USA (PO)